Corporate Milestones
| 2011 | Binding Site sell majority shares to private investment group, Nordic Capital. |
| 2011 | The Lord Mayor of Birmingham officially opens the new Birmingham headquarters. |
| 2011 | Binding Site relocates to new headquarters in Birmingham City Centre, UK. |
| 2011 | Patents granted for Hevylite® methodology. Patent number EP1842071 in Europe and by patent number 7,897,353 B2 in the USA. |
| 2010 | New Italian office founded in Bergamo. |
| 2010 | NCCN Clinical Practice Guidelines in Oncology publish recommendations for use of Freelite® in the initial diagnostic workup of multiple myeloma and related disorders. |
| 2010 | The Binding Site receives Queen's Award for Enterprise in the International Trade category. |
| 2010 | New Binding Site office is founded in Antwerp, Belgium to support customers in Belgium, Netherlands and Luxembourg. |
| 2010 | The Binding Site s.r.o., for Czech Republic and Slovak Republic, is founded in Prague, Czech Republic. |
| 2009 | Launch of Hevylite® in Europe for analysis of immunoglobulin heavy chain/light chain (HLC) pairs. |
| 2009 | Sale of Autoimmune business to Werfen Group. |
| 2008 | International Myeloma Working Group publish recommendations for use of Freelite® in screening, prognosis and treatment response in Leukemia. |
| 2008 | Launch of EuLite clinical trial using velcade-based chemotherapy and hemodialysis for the removal of serum free light chains as measured by Freelite®. |
| 2007 | First Binding Site SPAPLUS automated analyzer is placed in a Cancer Center in the USA to run Freelite® assays. |
| 2007 | Clinical utility of Freelite® for prognosis of multiple myeloma is published in Blood and British Journal of Haematology. |
| 2007 | Journal of the American Society of Nephrology publishes the first study using hemodialysis for the removal of serum free light chains as measured by Freelite®. |
| 2007 | The Binding Site receives Queen's Award for Enterprise in the Innovation category, for the Freelite® serum free light chain assay. |
| 2007 | The Binding Site Spain is founded in Barcelona. |
| 2007 | Number of DSX processors placed by The Binding Site in the USA reaches 150. |
| 2006 | Mayo Clinic publishes the first independent study in the USA recommending Freelite® as a routine screening test in Mayo Clinic Proceedings. |
| 2006 | Freelite® is incorporated into new International uniform response criteria for multiple myeloma published in Leukemia. |
| 2006 | Freelite® is incorporated into the National UK guidelines for the diagnosis and monitoring of Multiple Myeloma published in the British Journal of Haematology. |
| 2005 | First direct sales into Canada by The Binding Site Inc. |
| 2005 | International Consensus on Freelite® assays for AL amyloidosis is published in American Journal of Hematology. |
| 2004 | First National guidelines for the incorporation of Freelite® assays into the management of Primary Amyloidosis patients is published in the British Journal of Haematology. |
| 2003 | Publication highlighting the clinical utility of Freelite® for the replacement of Bence Jones protein appears in The Lancet. |
| 2001 | First publication highlighting the clinical significance of Freelite® in nonsecretory multiple myeloma patients is published in Blood. |
| 2001 | The Binding Site Inc signs a deal with Dynex technologies for distribution of their DSX fully automated EIA processor. |
| 1996 | The Binding Site France is founded in Grenoble. |
| 1993 | The Binding Site GmbH in Heidelberg, Germany is founded. Also this year, the Binding Site achieves worldwide leadership position in the human IgG subclass testing market. |
| 1992 | The Binding Site receives Queen's Award for Export Achievement. |
| 1990 | First FDA cleared commercially available human IgG subclass kits for routine automated clinical use is launched. |
| 1988 | The Binding Site Inc in San Diego, USA is founded. The product range and customer base for clinical research antibodies continues to grow. |
| 1987 | IgG Subclass RID kits are first launched for the investigation of immunodeficiency. |
| 1983 | The Binding Site Ltd is founded and launched with a range of highly specific polyclonal antisera used by clinical researchers worldwide. |
